BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites
SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing...
Month: June 2021
Walmart Extends Use of the Inovalon ONE® Platform
Retailer Extends Relationship with Inovalon to 2028BOWIE, Md., June 24, 2021 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider...
Major shareholder announcement
Orphazyme A/SCompany announcement No. 19/2021Company Registration No. 32266355 Copenhagen, Denmark, June 24, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a...
PRIMED, Traffic Tech and GlobalMedic Present: A Mask From Every Canadian to Keep Up The Fight Against COVID-19
MISSISSAUGA, Ontario, June 24, 2021 (GLOBE NEWSWIRE) -- PRIMED Medical Products partnering with GlobalMedic and Traffic Tech to donate 38...
Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on...
VitalHub Announces 5-Year Licensing Contract to implement and use the TREAT Client Management and Care Coordination Solution with Family Service Toronto
TORONTO, June 24, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the...
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’),...
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
Phase 2 trial expected to begin in the first quarter of 2022BASEL, Switzerland, June 24, 2021 (GLOBE NEWSWIRE) -- VectivBio...
Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4...
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement
4D-110: Initial clinical safety data at both of the two dose levels in the Phase 1 clinical trial indicate that...
Miromatrix Medical Announces Pricing of Upsized Initial Public Offering
EDEN PRAIRIE, Minn., June 24, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering...
Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
Primary endpoint, change in DUX4-driven gene expression which was included as an experimental biomarker, was not metLosmapimod showed statistically significant*...
Aileron Therapeutics to be Added to the Russell Microcap® Index
BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience...
Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally...
REPEAT – Silo Wellness Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley Family
MONTEGO BAY, Jamaica, June 24, 2021 (GLOBE NEWSWIRE) -- Silo Wellness Inc. (“Silo Wellness” or the “Company”) (CSE: SILO) (OTC:...
Trading update
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Trading update Operating profit strong and expected to be well ahead...
Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection
Company announcement – No. 41/ 2021 Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection ZEGALOGUE now available in...
AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
- Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing- - Dosing of pediatric...
Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma
Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of AVB-500HOUSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV),...
USA Equities Corp. Acquires AllergiEnd®Assets
●Acquisition Strengthens USAQ Business Model and Strategic Position●Purchase includes AllergiEnd® Method Patent, Trademark and Website●AllergiEnd®’s Product Portfolio Favorably Aligned with...